CRO Activity and Intel Report, 2025
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for 2025.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2025.
Scope
The 2025 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
This report will enable the user to answer the following questions –
What are the trends by region, therapy area, sites by CROs for the past year?
Who was the most active CRO in the past quarter?
Who were the most active sponsors by market cap in the past year?
What was the most widely studied therapy area in the past year vs. the previous year?
By region, who had the most clinical trials initiated in the past year?
By region, what were the Q4 2025 CRO invitations and appointments?
ICON
PPD
Clario
Labcorp Drug Development
Parexel
Syneos
Fortrea
Signant Health Management
WCG Clinical
AstraZeneca
Merck
Novartis
Pfizer
Eli Lilly
Jiangsu Hengrui Pharmaceuticals
CSPC Pharmaceutical Group
AbbVie
Sanofi
Bristol Myers Squibb
Haisco Pharmaceutical Group
Zhejiang Huahai Pharmaceutical
Zydus Lifesciences
Gan & Lee Pharmaceuticals
Shanghai Henlius Biotech
Apeloa Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Huadong Medicine
KeyMed Biosciences
Sichuan Kelun Pharmaceutical
Beijing Foyou Pharma
Boryung
Sinovac Biotech
Cisen Pharmaceutical
Daewoong
Chong Kun Dang Holdings
Daewoong Pharmaceutical
Dong-A ST
Tianjin Lisheng Pharmaceutical
Akebia Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Contract Research Organization reports